This article is more than 5 years old. Information may no longer be current.

VIDEO: Patients with microsatellite stable colorectal cancer show lack of response to ‘immunotherapy revolution’

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Patients with colorectal cancer and microsatellite stability receive “no benefit” from immunotherapy, according to J. Randolph Hecht, MD, of the David Geffen School of Medicine at UCLA.

Hecht describes the dearth of success seen with immunotherapy among this group of patients, which accounts for about 97% of all individuals with colorectal cancer. He reviews the potential reasons for this and ongoing research projects that are investigating how to best utilize immunotherapy in these patients.

“I think there is a huge amount of research that really is underway that, hopefully, will bring the immunotherapy revolution to the vast majority of people with metastatic colorectal cancer,” Hecht said.